Roche begins tender offer in Disetronic deal:
This article was originally published in Clinica
Roche began its tender offer to the shareholders of Burgdorf, Switzerland-based insulin pump group Disetronic on March 24. It is offering SwFr670 ($479) and two Roche non-voting equity shares per Disetronic share in its acquisition bid, which was announced last month (see Clinica No 1045, p 1). The tender period is scheduled to end on April 28, but can be extended by Roche if necessary; at least 80% of Disetronic's shareholders must accept the offer for it to go ahead.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.